V1RE5 Inhibitors
V1RE5 inhibitors constitute a class of chemical compounds that interact with a specific biological target identified by the nomenclature V1RE5. This target is typically a protein or receptor that plays a role in a particular biochemical pathway within an organism. The inhibitors are designed to bind to this protein or receptor, thereby modulating its function through a process of inhibition. The binding of these inhibitors is a highly specific interaction, often involving both the recognition of the protein's three-dimensional structure and the establishment of multiple non-covalent interactions such as hydrogen bonds, ionic interactions, van der Waals forces, and hydrophobic effects. The specificity is crucial to ensure that the inhibitors exert their action only on the intended target and not on other similar proteins or receptors in the organism, which could lead to unintended consequences.
The development and characterization of V1RE5 inhibitors involve a sophisticated understanding of molecular biology, chemistry, and pharmacodynamics. Scientists employ various techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computer-aided drug design (CADD) to elucidate the structure of the target protein and to design inhibitors that have a high affinity and selectivity for V1RE5. In the laboratory, these compounds are synthesized through a series of chemical reactions, purified, and then subjected to a battery of assays to confirm their inhibitory activity. The potency of an inhibitor is often quantified by its IC50 value, which represents the concentration of the inhibitor required to reduce the activity of V1RE5 by half. The lower the IC50 value, the more potent the inhibitor. Furthermore, the stability of these inhibitors under physiological conditions, their solubility in biological fluids, and their ability to reach the site of the target protein are critical factors that influence their design and selection.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, wortmannin can prevent the phosphorylation and activation of AKT, a downstream effector in the PI3K pathway. Since V1RE5 is regulated by the PI3K/AKT pathway, wortmannin leads to decreased V1RE5 activity by inhibiting this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. It binds to FKBP12 and the resulting complex inhibits mTORC1, which can downregulate protein synthesis and cell growth. V1RE5 activity is often modulated by mTOR pathways due to its role in cellular growth processes, so rapamycin can decrease V1RE5 activity by inhibiting mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Like wortmannin, LY294002 is a specific inhibitor of PI3K. By inhibiting PI3K, LY294002 prevents AKT activation, which is crucial for V1RE5 function. Consequently, V1RE5 activity is decreased due to reduced PI3K/AKT signaling. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the phosphorylation and activation of AKT without affecting other kinases. Reduced AKT activity leads to decreased activation of downstream targets, including V1RE5, thus diminishing its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, enzymes in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 prevents the activation of ERK, which could regulate V1RE5 by phosphorylation. Therefore, V1RE5 activity is indirectly decreased by U0126 through the inhibition of the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38 kinase, SB203580 can alter the phosphorylation state of proteins that control cell cycle or stress responses, indirectly affecting the activity of V1RE5. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which prevents the activation of ERK. Since the MAPK/ERK pathway can influence V1RE5 activity, inhibition by PD98059 leads to decreased function of V1RE5. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), part of the MAPK family. By inhibiting JNK, SP600125 can affect transcription factors and genes associated with cell survival and apoptosis, which may indirectly decrease the activity of V1RE5. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $173.00 $230.00 $275.00 $332.00 | 9 | |
BKM120 is a pan-class I PI3K inhibitor. By broadly inhibiting PI3K isoforms, BKM120 decreases AKT signaling, thereby reducing V1RE5 activity as part of the downstream effects. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor that also inhibits several other tyrosine kinases. By inhibiting Src family kinases, dasatinib disrupts several signaling pathways that may regulate V1RE5 activity, leading to its decreased function. | ||||||